TPST · Insider Trading
Tempest Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TPST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Nancy Freda Smith | Director | A | +25,000 deriv. | — |
| 2026-06-23 | Matthew Angel | CEO and President | Buy | +231,482 | +$500.00K |
| 2026-06-17 | John D. Yee | Director | A | +25,000 deriv. | — |
| 2026-06-08 | William Drake Richey | Director | A | +25,000 deriv. | — |
| 2026-04-02 | Nicholas Maestas | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-04-02 | Justin Trojanowski | Corporate Controller | A | +22,000 deriv. | — |
| 2026-03-25 | Matthew Angel | CEO and President | Buy | +231,482 | +$500.00K |
| 2026-02-06 | Matthew Angel | CEO and President | A | +269,621 deriv. | — |
| 2026-01-28 | Michael Raab | Director | A | +1,230 deriv. | — |
| 2026-01-28 | Ronit Simantov | Director | A | +1,230 deriv. | — |
| 2026-01-28 | Geoffrey Nichol | Director | A | +1,230 deriv. | — |
| 2026-01-28 | Christine A Pellizzari | Director | A | +1,230 deriv. | — |
| 2025-01-06 | Stephen R Brady | President and CEO | A | +550,000 deriv. | — |
| 2025-01-06 | Samuel Whiting | Chief Medical Officer | A | +270,000 deriv. | — |
| 2025-01-06 | Justin Trojanowski | Corporate Controller | A | +30,000 deriv. | — |
| 2025-01-06 | Nicholas Maestas | Chief Financial Officer | A | +200,000 deriv. | — |
| 2024-08-12 | Versant Side Fund IV, L.P. | 10%+ Owner | Sell | −7,091,991 | −$8.70M |
| 2024-07-08 | Stephen R Brady | President and CEO | Buy | +35,000 | +$73.85K |
| 2024-07-03 | Samuel Whiting | Chief Medical Officer | Buy | +4,672 | +$9.95K |
| 2024-07-02 | Justin Trojanowski | Corporate Controller | Buy | +7,500 | +$16.20K |
| 2024-06-14 | Christine A Pellizzari | Director | A | +16,000 deriv. | — |
| 2024-06-14 | Geoffrey Nichol | Director | A | +16,000 deriv. | — |
| 2024-06-14 | Ronit Simantov | Director | A | +16,000 deriv. | — |
| 2024-06-14 | Michael Raab | Director | A | +16,000 deriv. | — |
| 2024-01-05 | Samuel Whiting | Chief Medical Officer | A | +100,000 deriv. | — |
| 2024-01-05 | Nicholas Maestas | VP of Strategy and Finance | A | +40,000 deriv. | — |
| 2024-01-05 | Stephen R Brady | President and CEO | A | +250,000 deriv. | — |
| 2024-01-05 | Justin Trojanowski | Principal Accounting Officer | A | +26,500 deriv. | — |
| 2023-10-13 | Nicholas Maestas | VP of Strategy and Finance | A | +100,000 deriv. | — |
| 2023-10-13 | Justin Trojanowski | Corporate Controller | A | +55,000 deriv. | — |
| 2023-10-13 | Stephen R Brady | President and CEO | A | +725,000 deriv. | — |
| 2023-10-13 | Samuel Whiting | Chief Medical Officer | A | +325,000 deriv. | — |
| 2023-06-20 | Michael Raab | Director | A | +8,200 deriv. | — |
| 2023-06-20 | Christine A Pellizzari | Director | A | +8,200 deriv. | — |
| 2023-06-20 | Ronit Simantov | Director | A | +8,200 deriv. | — |
| 2023-06-20 | Geoffrey Nichol | Director | A | +8,200 deriv. | — |
| 2023-01-05 | Nicholas Maestas | VP of Strategy and Finance | A | +38,425 deriv. | — |
| 2023-01-05 | Samuel Whiting | Chief Medical Officer | A | +69,700 deriv. | — |
| 2023-01-05 | Thomas W. Dubensky | President | A | +102,700 deriv. | — |
| 2023-01-05 | Justin Trojanowski | Corporate Controller | A | +20,300 deriv. | — |
| 2023-01-05 | Stephen R Brady | Chief Executive Officer | A | +177,300 deriv. | — |
| 2022-10-04 | Justin Trojanowski | Corporate Controller | A | +2,500 deriv. | — |
| 2022-06-22 | Thomas W. Dubensky | President | A | +87,801 deriv. | — |
| 2022-06-22 | Stephen R Brady | Chief Executive Officer | A | +173,533 deriv. | — |
| 2022-06-22 | Geoffrey Nichol | Director | A | +3,500 deriv. | — |
| 2022-06-22 | Samuel Whiting | Chief Medical Officer | A | +55,680 deriv. | — |
| 2022-06-22 | Pierre Lorenzo | Corporate Controller | A | +8,477 deriv. | — |
| 2022-06-22 | Thomas Woiwode | Director | A | +3,500 deriv. | — |
| 2022-06-22 | Nicholas Maestas | VP of Strategy and Finance | A | +51,270 deriv. | — |
| 2022-06-22 | Michael Raab | Director | A | +3,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Matthew Angel | CEO and President | 5,068,552 | $2.59M |
| Stephen R Brady | President and CEO | 3,567 | $1.82K |
| Justin Trojanowski | Corporate Controller | 1,705 | $870 |
| Samuel Whiting | Chief Medical Officer | 736 | $376 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TPST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.